Skip to Main Content

The Trump administration may hand the pharmaceutical industry a gift, at least temporarily.

A controversial rule that would penalize drug makers for overcharging hospitals, clinics, and other providers for medicines that are purchased under the federal government’s 340B drug discount program may be delayed by nearly an entire year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!